Bicara Therapeutics earnings were -$102.7M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest BCAX earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$27.4M, down 25.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BCAX reported annual earnings of -$68.0M, with 30.8% growth.
Bicara Therapeutics Earnings Reports & History FAQ
What were Bicara Therapeutics's earnings last quarter?
On BCAX's earnings call on Invalid Date, Bicara Therapeutics (NASDAQ: BCAX) reported Q2 2025 earnings per share (EPS) of -$0.50, up 97.37% year over year. Total BCAX earnings for the quarter were -$27.39 million. In the same quarter last year, Bicara Therapeutics's earnings per share (EPS) was -$19.01.
Is Bicara Therapeutics profitable or losing money?
As of the last Bicara Therapeutics earnings report, Bicara Therapeutics is currently losing money. Bicara Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$102.67 million, a 58.34% increase year over year.
What was BCAX's earnings growth in the past year?
As of Bicara Therapeutics's earnings date in Invalid Date, Bicara Therapeutics's earnings has grown year over year. BCAX earnings in the past year totalled -$102.67 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.